Midas Letter and C-Suite are excited to announce Midas Letter LIVE. Midas Letter highlights the stocks and stories to watch in the Canadian markets today. Host James West is a recognized authority on investing in the emerging company segment having been a regularly featured guest on Business News Network, CNBC, Bloomberg, Reuters, and CTV. James West and guests provide comprehensive fundamental & technical analysis on all trending business and investment news, while interviewing the top CEOs of all public companies and analysts with the highest reputations in the business. Midas Letter is excited to feature all investing content on C-suite.
Khiron Life Sciences Corp (CVE:KHRN) President on Definitive Agreement to Acquire NettaGrowth
Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) President Chris Naprawa addresses the company’s recent stock volatility. Naprawa clears up a misconception created when the company announced it had signed a definitive agreement for the acquisition of NettaGrowth International. Naprawa explains the move was originally disclosed on January 25 and that the confusion stemmed from Khiron commencing US press releases with the announcement of the definitive agreement. Naprawa discusses the rapid evolution of the Latin American cannabis market and Khiron’s monitoring of changing regulatory frameworks. While Khiron is often grouped with domestic cultivators, it is more accurately described as a multi-jurisdiction medical and CPG company, according to Naprawa. Khiron is a leader in the emerging cannabis cosmeceutical space and Naprawa anticipates that the company’s CBD cosmetic products will be available in up to 400 stores in Colombia by the end of this quarter. Naprawa discusses the possibility of Kuida products being available in the US by the end of the year, as a result of Khiron’s JV with US-based Dixie Brands Inc (CNSX:DIXI.U) (OTCMKTS:DXBRF) (FRA:0QV).